SG11201402609RA - Compositions and methods for treating hepatitis c virus - Google Patents

Compositions and methods for treating hepatitis c virus

Info

Publication number
SG11201402609RA
SG11201402609RA SG11201402609RA SG11201402609RA SG11201402609RA SG 11201402609R A SG11201402609R A SG 11201402609RA SG 11201402609R A SG11201402609R A SG 11201402609RA SG 11201402609R A SG11201402609R A SG 11201402609RA SG 11201402609R A SG11201402609R A SG 11201402609RA
Authority
SG
Singapore
Prior art keywords
virus
compositions
methods
treating hepatitis
hepatitis
Prior art date
Application number
SG11201402609RA
Inventor
Darryl G Cleary
Charles J Reynolds
Miriam Michelle Berrey
Robert G Hindes
William T Symonds
Adrian S Ray
Hongmei Mo
Christy M Hebner
Reza Oliyai
Vahid Zia
Dimitrios Stefanidis
Rowchanak Pakdaman
Melissa Jean Casteel
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of SG11201402609RA publication Critical patent/SG11201402609RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201402609RA 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus SG11201402609RA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus
PCT/US2012/066605 WO2013082003A1 (en) 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
SG11201402609RA true SG11201402609RA (en) 2014-06-27

Family

ID=56291296

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402609RA SG11201402609RA (en) 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus

Country Status (22)

Country Link
EP (2) EP2785340B1 (en)
JP (2) JP5899327B2 (en)
KR (1) KR101560994B1 (en)
CN (1) CN104039319B (en)
AR (1) AR089578A1 (en)
AU (1) AU2012346217B2 (en)
BR (1) BR112014012739A8 (en)
CA (1) CA2856529C (en)
CO (1) CO6970603A2 (en)
EA (1) EA027296B1 (en)
EC (1) ECSP14005678A (en)
ES (1) ES2817886T3 (en)
HK (1) HK1202268A1 (en)
MD (1) MD4430C1 (en)
MX (1) MX2014006373A (en)
PE (1) PE20141296A1 (en)
PH (1) PH12014501133A1 (en)
SG (1) SG11201402609RA (en)
TW (1) TWI566773B (en)
UY (1) UY34474A (en)
WO (1) WO2013082003A1 (en)
ZA (1) ZA201404061B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4589C1 (en) 2011-09-16 2019-03-31 Gilead Pharmasset Llc Pharmaceutical composition comprising sofosbuvir and uses thereof for treating hepatitis C virus
NZ625087A (en) 2013-01-31 2017-05-26 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US20170080008A1 (en) * 2014-03-05 2017-03-23 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
EP3845221B1 (en) 2014-06-13 2023-12-13 Ratiopharm GmbH Solid state forms of sofosbuvir
EA201692515A1 (en) * 2014-06-23 2017-05-31 Сановель Илач Санайи Ве Тиджарет А.Ш. NEW PHARMACEUTICAL COMPOSITION ON THE BASIS OF SOFOSBUVIRA AND RIBAVIRIN
EA201692507A1 (en) * 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. PHARMACEUTICAL COMBINATIONS OF SOFOSBUVIR AND RIBAVIRIN
EP2959891A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
CN105267232A (en) * 2014-06-30 2016-01-27 康普药业股份有限公司 Pharmaceutical preparation for treating hepatitis C and preparing method thereof
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
WO2016055576A1 (en) * 2014-10-08 2016-04-14 Sandoz Ag High drug load tablets comprising sofosbuvir
CN104546783A (en) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 Sofosbuvir film coating tablet preparation and preparation method thereof
CN104622836B (en) * 2014-12-23 2020-02-21 浙江华海药业股份有限公司 Sofosbuvir coated tablet and preparation method thereof
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
CN104586802B (en) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 A kind of pharmaceutical composition containing Suo Feibuwei
WO2016156330A1 (en) * 2015-03-30 2016-10-06 Ratiopharm Gmbh Solid pharmaceutical composition comprising amorphous sofosbuvir and a phospholipid
CN104840964B (en) * 2015-05-07 2018-01-16 南京正大天晴制药有限公司 A kind of rope fluorine cloth Wei pharmaceutical composition of stabilization and preparation method thereof
CZ2015443A3 (en) 2015-06-26 2017-01-04 Zentiva, K.S. Sofosbuvir pharmaceutical formulation
CN104906062B (en) * 2015-06-30 2018-05-25 浙江天顺生物科技有限公司 A kind of tablet of Suo Feibuwei and preparation method thereof
BR102017011025A2 (en) 2016-06-02 2017-12-19 Gilead Pharmasset Llc FORMULATION OF COMBINATION OF THREE ANTIVIRAL COMPOUNDS
US20190185507A1 (en) 2016-08-19 2019-06-20 Sandoz Ag Sofosbuvir Derivatives for the Treatment of Hepatitis C
CZ2016553A3 (en) 2016-09-09 2018-03-21 Zentiva, K.S. A solid pharmaceutical dosage form containing sofosbuvir
CN106667936B (en) * 2016-12-31 2021-02-05 江苏科本药业有限公司 Sofosbuvir tablet and preparation method thereof
CN106880642B (en) * 2017-02-17 2019-08-06 杭州青玥医药科技有限公司 Rope fluorine cloth Wei pharmaceutical composition and preparation method thereof
CN107041873B (en) * 2017-02-17 2020-02-28 杭州青玥医药科技有限公司 Preparation method of sofosbuvir coated tablet
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR20200043618A (en) 2018-10-18 2020-04-28 주식회사유한양행 Pharmaceutical composition for oral administration comprising an aminopyrimidine derivative or its salt
CN110604726B (en) * 2019-07-19 2022-06-07 株洲千金药业股份有限公司 Sofosbuvir composition and application thereof
CN111072742B (en) * 2019-12-23 2022-12-02 南京正大天晴制药有限公司 Novel crystal form of medicine for treating hepatitis C and composition thereof
CN111973566A (en) * 2020-07-23 2020-11-24 石药集团中奇制药技术(石家庄)有限公司 Sofosbuvir tablet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
EP2495249A1 (en) * 2007-02-26 2012-09-05 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2369321T3 (en) 2007-09-14 2011-11-29 Schering Corporation PROCEDURE FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C.
DE102007052070A1 (en) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg candesartancilexetil
DE102008057284A1 (en) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Preparation of tablets containing lenalidomide and adhesion promoter, where the tablets are produced by dry granulation or direct compression, useful e.g. for stimulating erythropoiesis and as an immunomodulator
US8445430B2 (en) * 2008-11-20 2013-05-21 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus
DE102009015702A1 (en) * 2009-03-31 2010-10-07 Ratiopharm Gmbh Tablets containing dapoxetine and dry processing for their preparation
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (en) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
EP2467144A1 (en) * 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
EP2752422B1 (en) * 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype

Also Published As

Publication number Publication date
MD4430C1 (en) 2017-03-31
HK1202268A1 (en) 2015-09-25
EP2785340B1 (en) 2020-07-15
CA2856529C (en) 2018-03-06
KR101560994B1 (en) 2015-10-15
UY34474A (en) 2013-06-28
JP5899327B2 (en) 2016-04-06
JP2014533733A (en) 2014-12-15
ES2817886T3 (en) 2021-04-08
MX2014006373A (en) 2014-07-22
EA027296B1 (en) 2017-07-31
AR089578A1 (en) 2014-09-03
PH12014501133B1 (en) 2014-09-01
PH12014501133A1 (en) 2014-09-01
WO2013082003A1 (en) 2013-06-06
BR112014012739A8 (en) 2017-06-20
ZA201404061B (en) 2016-09-28
CA2856529A1 (en) 2013-06-06
CN104039319A (en) 2014-09-10
JP2016053096A (en) 2016-04-14
EA201490903A1 (en) 2014-11-28
KR20140108645A (en) 2014-09-12
AU2012346217B2 (en) 2016-02-04
ECSP14005678A (en) 2015-12-31
EP2785340A1 (en) 2014-10-08
CO6970603A2 (en) 2014-06-13
BR112014012739A2 (en) 2017-06-13
EP3777867A1 (en) 2021-02-17
NZ625532A (en) 2016-07-29
CN104039319B (en) 2017-12-29
MD20140058A2 (en) 2014-11-30
TWI566773B (en) 2017-01-21
TW201325599A (en) 2013-07-01
AU2012346217A1 (en) 2014-06-19
MD4430B1 (en) 2016-08-31
PE20141296A1 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
SG11201402609RA (en) Compositions and methods for treating hepatitis c virus
HRP20181564T1 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
ZA201306720B (en) Hepatitis c virus inhibitors
IL229270B (en) Hepatitis c virus inhibitors
EP2768517A4 (en) Hepatitis c virus inhibitors
EP2688592A4 (en) Compositions and methods to immunize against hepatitis c virus
HK1208364A1 (en) Method for treating hepatitis c virus infection using quercetin- containing compositions
ZA201309356B (en) Hepatitis c virus inhibitors
HK1209319A1 (en) Methods for treating hepatitis c
HK1212332A1 (en) Hepatitis c virus inhibitors
EP2802353A4 (en) Compositions and methods for treating viral infections
EP2869821A4 (en) Compositions and methods for treating and inhibiting viral infections
EP2663327A4 (en) Compositions and methods for treating viral infections
HK1209320A1 (en) Methods for treating hepatitis c
ZA201207226B (en) Compositions and methods for treating viral diseases
SG11201402899TA (en) Methods and compositions for treating viral diseases
EP2838903A4 (en) Methods and compositions for treating viral infections
IL232889A0 (en) Compositions and methods for treating hepatitis c virus
HK1199617A1 (en) Compositions and methods for treating viral diseases